Aralez Pharmaceuticals Company Profile (NASDAQ:ARLZ)

About Aralez Pharmaceuticals (ARLZ)

Aralez Pharmaceuticals logoAralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: ARLZ
  • CUSIP: 73941U10
Key Metrics:
  • Previous Close: $2.19
  • 50 Day Moving Average: $3.60
  • 200 Day Moving Average: $4.49
  • 52-Week Range: $65,683,000.00 - $2.05
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.04
  • P/E Growth: -0.07
  • Market Cap: $143.85M
  • Outstanding Shares: 65,683,000
  • Beta: 1.15
  • Net Margins: -211.76%
  • Return on Equity: -65.67%
  • Return on Assets: -38.32%
  • Debt-to-Equity Ratio: 0.50%
  • Current Ratio: 2.40%
  • Quick Ratio: 2.25%

Analyst Ratings

Consensus Ratings for Aralez Pharmaceuticals (NASDAQ:ARLZ) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $8.75 (299.54% upside)

Analysts' Ratings History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/15/2017Chardan CapitalLower Price TargetBuy -> Buy$10.00 -> $5.50HighView Rating Details
11/8/2016Bloom BurtonReiterated RatingAccumulateN/AView Rating Details
10/10/2016GuggenheimSet Price TargetBuy$12.00N/AView Rating Details
3/16/2016Dundee SecuritiesLower Price TargetBuy$10.00 -> $9.00N/AView Rating Details
(Data available from 3/26/2015 forward)


Earnings History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Earnings by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Earnings History by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/201712/31/2016($0.26)($0.37)$21.86 million$20.00 millionViewListenView Earnings Details
11/7/2016Q316($0.29)($0.32)$12.23 million$136.00 millionViewListenView Earnings Details
8/9/2016Q216($0.19)($0.27)$9.70 million$12.60 millionViewListenView Earnings Details
5/10/2016Q116($0.25)($0.73)$9.70 million$8.10 millionViewListenView Earnings Details
3/15/2016Q415($0.28)($0.40)$9.25 million$5.97 millionViewListenView Earnings Details
11/9/2015Q315($0.26)($0.25)$5.20 million$5.80 millionViewListenView Earnings Details
8/10/2015Q215$0.04($0.50)$4.60 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115$0.05$0.01$4.70 million$4.40 millionViewListenView Earnings Details
3/9/2015Q414$0.17$0.21$8.55 million$9.90 millionViewListenView Earnings Details
11/6/2014Q314$0.09$0.20$7.50 million$7.50 millionViewListenView Earnings Details
8/7/2014Q214$0.07$0.09$7.10 million$7.40 millionViewListenView Earnings Details
5/8/2014Q1($0.04)$0.09$5.50 million$7.55 millionViewListenView Earnings Details
3/5/2014Q413($0.05)($0.07)$4.35 million$4.70 millionViewListenView Earnings Details
11/6/2013Q313($0.09)($0.16)$3.25 million$2.60 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.20)($0.13)$1.30 million$1.70 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.19)($0.19)$1.43 million$1.40 millionViewListenView Earnings Details
3/6/2013Q4 2012($0.21)($0.20)$1.46 million$1.40 millionViewListenView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.73 million$0.90 millionViewN/AView Earnings Details
8/1/2012($0.25)($0.17)ViewN/AView Earnings Details
5/1/2012($0.28)($0.28)ViewN/AView Earnings Details
2/28/2012$2.00$2.04ViewN/AView Earnings Details
11/3/2011($0.24)($0.24)ViewN/AView Earnings Details
7/28/2011($0.19)($0.21)ViewN/AView Earnings Details
5/5/2011($0.23)($0.19)ViewN/AView Earnings Details
3/9/2011$0.56$0.61ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Current Year EPS Consensus Estimate: $-1.07 EPS
Next Year EPS Consensus Estimate: $-0.72 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.36)($0.36)($0.36)
Q3 20161($0.39)($0.39)($0.39)
Q4 20161($0.40)($0.40)($0.40)
Q1 20171($0.48)($0.48)($0.48)
Q2 20171($0.47)($0.47)($0.47)
Q3 20171($0.42)($0.42)($0.42)
Q4 20171($0.36)($0.36)($0.36)
(Data provided by Zacks Investment Research)


Dividend History by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Insider Ownership Percentage: 6.77%
Institutional Ownership Percentage: 44.01%
Insider Trades by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Institutional Ownership by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Insider Trades by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/20/2017Andrew I KovenInsiderSell7,825$2.41$18,858.25View SEC Filing  
3/20/2017Scott J CharlesCFOSell5,205$2.41$12,544.05View SEC Filing  
3/15/2017Adrian AdamsCEOBuy500,000$2.46$1,230,000.00View SEC Filing  
3/15/2017Arthur S KirschDirectorBuy45,000$2.27$102,150.00View SEC Filing  
3/15/2017James Patrick TursiInsiderBuy4,750$2.11$10,022.50View SEC Filing  
11/29/2016Robert Paul HarrisDirectorSell104,778$4.99$522,842.22View SEC Filing  
11/28/2016Robert Paul HarrisDirectorSell20,000$4.65$93,000.00View SEC Filing  
11/14/2016Kenneth B Lee JrDirectorBuy1,000$4.95$4,950.00View SEC Filing  
11/11/2016Seth RudnickDirectorBuy30,000$4.77$143,100.00View SEC Filing  
9/15/2016Robert Paul HarrisDirectorSell150,000$5.82$873,000.00View SEC Filing  
5/20/2016James Patrick TursiInsiderBuy10,000$3.75$37,500.00View SEC Filing  
5/16/2016Eric TrachtenbergInsiderBuy10,000$3.76$37,600.00View SEC Filing  
5/13/2016Kenneth B Lee JrDirectorBuy1,000$3.50$3,500.00View SEC Filing  
5/12/2016Andrew I KovenInsiderBuy71,500$3.49$249,535.00View SEC Filing  
5/12/2016Arthur S KirschDirectorBuy27,500$3.49$95,975.00View SEC Filing  
5/12/2016Scott J CharlesCFOBuy50,000$3.49$174,500.00View SEC Filing  
12/3/2015John R PlachetkaMajor ShareholderSell23,479$8.14$191,119.06View SEC Filing  
11/13/2015John R PlachetkaMajor ShareholderSell150,000$7.00$1,050,000.00View SEC Filing  
11/12/2015Adrian AdamsCEOBuy1,000,000$6.55$6,550,000.00View SEC Filing  
9/10/2015John E. BarnhardtVPSell18,322$8.78$160,867.16View SEC Filing  
6/18/2015John G FortInsiderSell78,905$10.93$862,431.65View SEC Filing  
6/3/2015Gilda Marie ThomasInsiderSell23,555$7.53$177,369.15View SEC Filing  
4/15/2015Gilda Marie ThomasInsiderSell25,000$8.61$215,250.00View SEC Filing  
3/17/2015Gilda Marie ThomasInsiderSell50,000$7.51$375,500.00View SEC Filing  
1/2/2015Gilda Marie ThomasVPSell25,000$7.91$197,750.00View SEC Filing  
12/1/2014Par Investment Partners LpMajor ShareholderBuy500,000$7.50$3,750,000.00View SEC Filing  
11/18/2014John R PlachetkaCEOSell50,000$9.00$450,000.00View SEC Filing  
11/6/2014John R PlachetkaCEOSell50,000$9.08$454,000.00View SEC Filing  
10/9/2014John R PlachetkaCEOSell50,000$8.12$406,000.00View SEC Filing  
10/8/2014John R PlachetkaCEOSell32,227$8.16$262,972.32View SEC Filing  
9/30/2014John R PlachetkaCEOSell50,000$7.48$374,000.00View SEC Filing  
9/29/2014John R PlachetkaCEOSell38,298$7.53$288,383.94View SEC Filing  
9/15/2014Dennis L McnamaraEVPSell4,275$7.85$33,558.75View SEC Filing  
9/9/2014John R PlachetkaCEOSell50,000$8.24$412,000.00View SEC Filing  
9/8/2014John R PlachetkaCEOSell30,000$8.30$249,000.00View SEC Filing  
8/25/2014John E BarnhardtVPSell4,293$8.25$35,417.25View SEC Filing  
8/20/2014John R PlachetkaCEOSell50,000$7.78$389,000.00View SEC Filing  
8/8/2014John R PlachetkaCEOSell50,000$7.75$387,500.00View SEC Filing  
7/30/2014John R PlachetkaCEOSell50,000$7.34$367,000.00View SEC Filing  
7/9/2014John R PlachetkaCEOSell50,000$8.88$444,000.00View SEC Filing  
7/8/2014John R PlachetkaCEOSell33,551$8.87$297,597.37View SEC Filing  
7/2/2014William L HodgesCFOSell11,414$9.05$103,296.70View SEC Filing  
6/23/2014John E BarnhardtVPSell27,484$8.80$241,859.20View SEC Filing  
6/23/2014William L HodgesCFOSell5,688$9.05$51,476.40View SEC Filing  
6/20/2014William L HodgesCFOSell50,000$9.05$452,500.00View SEC Filing  
6/19/2014William L HodgesCFOSell9,516$9.05$86,119.80View SEC Filing  
6/17/2014William L HodgesCFOSell112,156$9.03$1,012,768.68View SEC Filing  
6/16/2014Dennis L McnamaraEVPSell15,100$9.06$136,806.00View SEC Filing  
6/11/2014Arthur S KirschDirectorSell9,430$9.30$87,699.00View SEC Filing  
6/5/2014Arthur S KirschDirectorSell2,500$8.67$21,675.00View SEC Filing  
6/2/2014Arthur S KirschDirectorSell2,500$8.73$21,825.00View SEC Filing  
5/27/2014Arthur S KirschDirectorSell10,000$8.38$83,800.00View SEC Filing  
5/22/2014John BarnhardtVPSell77,840$8.31$646,850.40View SEC Filing  
5/16/2014John FortInsiderSell4,000$8.49$33,960.00View SEC Filing  
5/16/2014William HodgesCFOSell71,003$8.16$579,384.48View SEC Filing  
4/24/2014John FortInsiderSell13,725$9.61$131,897.25View SEC Filing  
12/20/2013John FortInsiderSell22,500$9.63$216,675.00View SEC Filing  
7/17/2013Par Investment Partners LpMajor ShareholderBuy90,000$5.25$472,500.00View SEC Filing  
12/27/2012John E BarnhardtVPSell5,219$5.25$27,399.75View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Latest Headlines for Aralez Pharmaceuticals (NASDAQ:ARLZ)
DateHeadline logoAralez Pharmaceuticals (ARLZ): Adrian Adams CEO Purchased 500,000 Shares Last Week: An Update And Interview - March 25 at 8:36 PM logoARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E - March 23 at 10:04 PM logoAndrew I. Koven Sells 7,825 Shares of Aralez Pharmaceuticals Inc (ARLZ) Stock - March 22 at 8:34 PM logoAralez Pharmaceuticals Inc (ARLZ) CFO Sells $12,544.05 in Stock - March 22 at 8:32 PM logoAralez Pharmaceuticals Inc (ARLZ) Price Target Cut to $5.50 by Analysts at Chardan Capital - March 21 at 7:58 AM logoAralez Pharmaceuticals Inc (ARLZ) Forecasted to Post Q1 2017 Earnings of ($0.48) Per Share - March 20 at 9:55 AM logoAralez CEO Purchases 500,000 Shares Of Company Common Stock On Open Market - March 20 at 8:34 AM logoAralez Pharmaceuticals Inc (ARZ) Director Buys C$11,850.00 in Stock - March 17 at 9:07 PM logoInsider Buying: Aralez Pharmaceuticals Inc (ARZ) Insider Acquires 4,750 Shares of Stock - March 17 at 9:06 PM logoAralez Pharmaceuticals Inc (ARLZ) Insider James Patrick Tursi Purchases 4,750 Shares - March 17 at 9:06 PM logoARLZ: 2016 Financial Results and Guidance for 2017 - March 16 at 5:07 PM logoARALEZ PHARMACEUTICALS INC. Financials - March 16 at 5:07 PM logoAralez Pharmaceuticals' (ARLZ) CEO Adrian Adams on Q4 2016 Results - Earnings Call Transcript - March 14 at 3:32 PM logoMid-Day Market Update: AMEC Foster Wheeler Surges Following Wood Group Bid; Aralez Pharmaceuticals Shares ... - Benzinga - March 14 at 5:49 AM logoWhy Aralez Pharmaceuticals Inc. Got Slaughtered Today - March 13 at 4:00 PM logoBUZZ-US STOCKS ON THE MOVE-Intel, Kronos, Aethlon, Aralez, Ciber - Nasdaq - March 13 at 3:43 PM logoMid-Day Market Update: AMEC Foster Wheeler Surges Following Wood Group Bid; Aralez Pharmaceuticals Shares ... - Nasdaq - March 13 at 3:43 PM logoAralez Pharmaceuticals Inc Earnings Call scheduled for 9:00 am ET today - March 13 at 3:43 PM logoAralez Reports Fourth Quarter And Full-Year 2016 Financial Results - March 13 at 8:34 AM logoARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosu - March 13 at 8:34 AM logoQ4 2016 Aralez Pharmaceuticals Inc Earnings Release - Before Market Open - March 13 at 8:34 AM logoARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement - March 2 at 3:51 PM logoAralez Pharmaceuticals (ARLZ) Presents at RBC Capital Markets Global Healthcare Conference 2017-Slideshow - February 22 at 8:38 PM logoAralez to Present at the RBC Capital Markets Global Healthcare Conference - Yahoo Finance - February 17 at 6:29 PM logoOutside the Box: Trump’s tax reform looks like just another of his tweets - February 16 at 7:54 PM logoAralez Pharmaceuticals Inc. (Nasdaq: ARLZ) to Ring The Nasdaq Stock Market Closing Bell - Nasdaq - February 14 at 9:18 PM logoResearch Reports Coverage on Biotech Stocks -- Cerulean Pharma, AveXis, TG Therapeutics, and Aralez Pharma - PR Newswire (press release) - February 8 at 3:52 PM logoPremarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen - - January 27 at 9:34 PM logoARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Other Events - January 27 at 4:32 PM logoARLZ: Aralez Attains Formulary Status for YOSPRALA™ from Express Scripts and CVS Caremark - January 25 at 3:43 PM logoAralez Announces Issuance Of Additional U.S. Patent For Yosprala - Yahoo Finance - January 12 at 1:58 AM logoAralez Announces Issuance Of Additional U.S. Patent For Yosprala - January 11 at 3:52 PM logoAralez Pharma (ARLZ) Submits MMA for PA10040 in Europe - - January 10 at 3:40 PM logoAralez Pharma (ARLZ) Submits MMA for PA10040 in Europe - January 9 at 3:55 PM logoAralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040 - January 9 at 3:55 PM logoAralez Pharmaceuticals (ARLZ) Dips on Product Launch - December 19 at 3:55 PM logoAralez Announces Commercial Launch Of BLEXTEN™ In Canada - December 19 at 3:55 PM


Frequently Asked Questions for Aralez Pharmaceuticals (NASDAQ:ARLZ)

What is Aralez Pharmaceuticals' stock symbol?

Aralez Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARLZ."

How were Aralez Pharmaceuticals' earnings last quarter?

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) issued its quarterly earnings data on Monday, March, 13th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.11. The company earned $20 million during the quarter, compared to the consensus estimate of $21.86 million. Aralez Pharmaceuticals had a negative net margin of 211.76% and a negative return on equity of 65.67%. Aralez Pharmaceuticals's revenue for the quarter was up 233.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.40) EPS.

When will Aralez Pharmaceuticals make its next earnings announcement?

Aralez Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.

Where is Aralez Pharmaceuticals' stock going? Where will Aralez Pharmaceuticals' stock price be in 2017?

3 brokers have issued 12-month price targets for Aralez Pharmaceuticals' stock. Their predictions range from $5.50 to $12.00. On average, they expect Aralez Pharmaceuticals' stock price to reach $8.75 in the next twelve months.

Who owns Aralez Pharmaceuticals stock?

Aralez Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Broadfin Capital LLC (7.32%), Armistice Capital LLC (4.33%), JW Asset Management LLC (4.10%), Tiger Legatus Capital Management LLC (3.03%), Deerfield Management Co. (2.51%) and Dimensional Fund Advisors LP (0.48%). Company insiders that own Aralez Pharmaceuticals stock include Adrian Adams, Andrew I Koven, Arthur S Kirsch, Eric Trachtenberg, Gilda Marie Thomas, James Patrick Tursi, John E Barnhardt, John G Fort, John R Plachetka, Kenneth B Lee Jr, Robert Paul Harris, Scott J Charles and Seth Rudnick.

Who sold Aralez Pharmaceuticals stock? Who is selling Aralez Pharmaceuticals stock?

Aralez Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Ancora Advisors LLC, GSA Capital Partners LLP and Putnam Investments LLC. Company insiders that have sold Aralez Pharmaceuticals stock in the last year include Andrew I Koven, Robert Paul Harris and Scott J Charles.

Who bought Aralez Pharmaceuticals stock? Who is buying Aralez Pharmaceuticals stock?

Aralez Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Broadfin Capital LLC, Norges Bank, JW Asset Management LLC, Glacier Peak Capital LLC, J. Goldman & Co LP, Tiger Legatus Capital Management LLC and Dynamic Technology Lab Private Ltd. Company insiders that have bought Aralez Pharmaceuticals stock in the last two years include Adrian Adams, Andrew I Koven, Arthur S Kirsch, Eric Trachtenberg, James Patrick Tursi, Kenneth B Lee Jr, Scott J Charles and Seth Rudnick.

How do I buy Aralez Pharmaceuticals stock?

Shares of Aralez Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aralez Pharmaceuticals stock cost?

One share of Aralez Pharmaceuticals stock can currently be purchased for approximately $2.19.

Aralez Pharmaceuticals (ARLZ) Chart for Sunday, March, 26, 2017

This page was last updated on 3/26/2017 by Staff